7 recruiting, 3 not yet recruiting, 1 withdrawn. 4 Phase 2, 3 Phase 1, 3 Phase 3, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 4 |
| Phase 1 | 3 | Recruiting 3 |
| Phase 3 | 3 | Not yet recruiting 1, Recruiting 1, Withdrawn 1 |
| Early Phase 1 | 1 | Not yet recruiting 1 |
| Not applicable | 1 | Not yet recruiting 1 |
Follow Follicular Lymphoma ( FL): new trials by email Literature Review of Follicular Lymphoma ( FL) trials Research Report on Follicular Lymphoma ( FL)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell Malignancies Lacutoclax+Rocbrutinib - Mantle Cell Lymphoma (MCL), Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 / Phase 2 | Recruiting | Guangzhou Lupeng Pharmaceutical Company LTD. | 92 | 2026-07-14 | 2026-07-30 |
| Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors Connected home blood pressure monitoring with daily IPA supervision. - Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL) | Not applicable | Not yet recruiting | Centre Hospitalier de la côte Basque | 40 | 2026-07-01 | 2026-06-22 |
| A Multicenter, Prospective, Open-Label, Randomized Controlled Clinical Study of Orelabrutinib Combined With Obinutuzumab and Lenalidomide Versus Obinutuzumab Plus Chemotherapy for Treatment-Naive Follicular Lymphoma Orelabrutinib, obinutuzumab, Lenalidomide - Follicular Lymphoma ( FL) | Phase 3 | Not yet recruiting | Ruijin Hospital | 652 | 2026-07-01 | 2026-07-22 |
| This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma LTZ-301 - Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma | Phase 1 | Recruiting | LTZ Therapeutics, Inc. | 42 | 2026-01-29 | 2026-07-24 |
| A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies None - Observational Study - Acute Myeloid Leukaemia (AML), Follicular Lymphoma ( FL) | Recruiting | Tempus AI | 550 | 2026-01-27 | 2026-10-09 | |
| Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell Lymphoma Conditioning chemotherapy followed by AbTCR (anti-CD19/CD22)-T cell infusion - Diffuse Large B Cell Lymphoma (DLBCL), Follicular Lymphoma ( FL) | Early Phase 1 | Not yet recruiting | First Affiliated Hospital Xi'an Jiaotong University | 3 | 2025-12-31 | 2025-09-17 |
| Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell Lymphoma Autoleucel (Relmacabtagene Autoleucel), Sintilimab (PD-1 inhibitor) - Large B Cell Diffuse Lymphoma, Mantle Cell Lymphoma (MCL) | Phase 2 | Recruiting | Sun Yat-sen University | 30 | 2025-09-15 | 2026-01-21 |
| NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19) Talikabtagene Autoleucel - Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL), Relapsed/Refractory Non-Hodgkin Lymphoma | Phase 2 / Phase 3 | Recruiting | Health Institutes of Turkey | 40 | 2025-09-11 | 2026-03-30 |
| A Study to Evaluate the Safety and Clinical Activity of GF- CART01 (CD20/19 CAR T Cell) in Subjects With Relapsed or Refractory B-Cell Hematological Malignancies GF-CART01 - Diffuse Large B Cell Lymphoma Relapsed, Diffuse Large B Cell Lymphoma Refractory | Phase 1 | Recruiting | GenomeFrontier Therapeutics TW Co., Ltd. | 18 | 2025-06-09 | 2026-06-12 |
| Zanubrutinib Combined With G-CVP in Previously Untreated FL zanubrutinib, obinutuzumab,combined with CVP - Follicular Lymphoma ( FL) | Phase 2 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 40 | 2025-01-01 | 2025-05-07 |
| To Evaluate Efficacy and Safety of Parsaclisib Plus Either Rituximab or Obinutuzumab in R/R Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) (CITADEL-302) parsaclisib, rituximab, obinutuzumab - Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL) | Phase 3 | Withdrawn | Incyte Corporation | 2022-12-30 | 2022-07-18 |
Lymphoma, Follicular (11) · Lymphoma, Large B-Cell, Diffuse (4) · Lymphoma, Mantle-Cell (4) · Lymphoma, B-Cell, Marginal Zone (3) · Burkitt Lymphoma (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lymphoma, B-Cell (2) · Recurrence (2) · Waldenstrom Macroglobulinemia (2) · Cytokine Release Syndrome (1) · Dendritic Cell Sarcoma, Interdigitating (1) · Hematologic Neoplasms (1) · Hypertension (1) · Leukemia, Myeloid, Acute (1) · Lymphoma, Non-Hodgkin (1)
Hemic and Lymphatic Diseases (11) · Immune System Diseases (11) · Immunoproliferative Disorders (11) · Lymphatic Diseases (11) · Lymphoma (11) · Lymphoproliferative Disorders (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Lymphoma, Non-Hodgkin (10) · Lymphoma, B-Cell (5) · Disease Attributes (4) · Pathologic Processes (4) · Pathological Conditions, Signs and Symptoms (4) · Hematologic Diseases (3) · Leukemia (3)
obinutuzumab (3) · Bendamustine Hydrochloride (1) · COP protocol 2 (1) · Cyclophosphamide (1) · Doxorubicin (1) · Immune Checkpoint Inhibitors (1) · Lenalidomide (1) · Prednisone (1) · Rituximab (1) · Therapeutics (1) · Vincristine (1) · orelabrutinib (1) · parsaclisib (1) · relmacabtagene autoleucel (1) · sintilimab (1)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Centre Hospitalier de la côte Basque (1) · First Affiliated Hospital Xi'an Jiaotong University (1) · GenomeFrontier Therapeutics TW Co., Ltd. (1) · Guangzhou Lupeng Pharmaceutical Company LTD. (1) · Health Institutes of Turkey (1) · Incyte Corporation (1) · LTZ Therapeutics, Inc. (1) · Ruijin Hospital (1) · Sun Yat-sen University (1) · Tempus AI (1)
China (5) · United States (2) · Taiwan (1) · Turkey (Türkiye) (1)
Michael Thompson, MD, PhD, FASCO (1) · Pengcheng He, M.D. (1)